Daewoong Pharmaceutical Co. LTD.: Diabetes Mellitus, Type 2 trials
The registry lists 20 Diabetes Mellitus, Type 2 studies with Daewoong Pharmaceutical Co. LTD. as lead sponsor. 6 are open to participants now and 0 have results posted.
Phase 1 4Phase 2 1Phase 3 10No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes MellitusNot yet recruitingNCT07619833Phase 3
- A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult VolunteersRecruitingNCT07539415Phase 1
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or DyslipidemiaRecruitingNCT06647888
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes MellitusNot yet recruitingNCT06141980Phase 3
- To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic FunctionRecruitingNCT05747664Phase 1
- A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusRecruitingNCT05466643Phase 3
- Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes MellitusActive, not recruitingNCT06427083
- Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes MellitusActive, not recruitingNCT06419816
- To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes MellitusActive, not recruitingNCT05926414
- To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose CombinationStatus unknownNCT05737771Phase 1
- The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminActive, not recruitingNCT05505994Phase 3
- Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on MetforminCompletedNCT05376969Phase 3
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.CompletedNCT05376930Phase 3
- Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)CompletedNCT04926623Not applicable
- The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes MellitusCompletedNCT04654390Phase 3
- The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.CompletedNCT04634500Phase 3
- The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.CompletedNCT04632862Phase 3
- Type 2 Diabetes Patients With Renal ImpairmentStatus unknownNCT04221399Phase 1
- Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes MellitusStatus unknownNCT04014023Phase 2
- Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)CompletedNCT02947620Phase 3